Literature DB >> 9278438

Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53.

S P Mathupala1, C Heese, P L Pedersen.   

Abstract

The p53 tumor suppressor is found to be mutated and abundant in a wide variety of tumors. Within tumors showing rapid growth, the Type II isoform of hexokinase is also highly expressed to facilitate high rates of glucose catabolism, which in turn promote their rapid proliferation. We previously reported isolation of the proximal promoter of the Type II hexokinase gene from the highly glycolytic hepatoma AS-30D (Mathupala, S. P., Rempel, A., and Pedersen, P. L. (1995) J. Biol. Chem. 270, 16918-16925). Here, we show that a p53 protein, exhibiting two point mutations in its cDNA, is abundantly expressed in the AS-30D hepatoma. Co-expression studies showed that p53 overexpression significantly and reproducibly activated the Type II hexokinase promoter. Two functional p53 motifs were identified within this promoter by footprint and gel retardation analyses. Presence of functional p53 response elements on the Type II hexokinase promoter and the positive regulatory effect on the promoter by the mutant p53 indicates that in rapidly growing liver tumors, and perhaps in many other tumors as well, this highly abundant p53 protein plays a role in maintaining a high glycolytic rate. This is the first report of a possible link between loss of cell cycle control in rapidly growing cancer cells and their high glycolytic phenotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278438     DOI: 10.1074/jbc.272.36.22776

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  100 in total

Review 1.  p53 regulation of metabolic pathways.

Authors:  Eyal Gottlieb; Karen H Vousden
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-02       Impact factor: 10.005

Review 2.  Genetic insights into OXPHOS defect and its role in cancer.

Authors:  Dhyan Chandra; Keshav K Singh
Journal:  Biochim Biophys Acta       Date:  2010-11-11

Review 3.  Alterations of metabolic genes and metabolites in cancer.

Authors:  Eric K Oermann; Jing Wu; Kun-Liang Guan; Yue Xiong
Journal:  Semin Cell Dev Biol       Date:  2012-01-28       Impact factor: 7.727

Review 4.  The role of p53 in cell metabolism.

Authors:  Xing-ding Zhang; Zheng-hong Qin; Jin Wang
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 5.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Semin Cancer Biol       Date:  2008-12-03       Impact factor: 15.707

6.  Altered glucose metabolism in Harvey-ras transformed MCF10A cells.

Authors:  Wei Zheng; Fariba Tayyari; G A Nagana Gowda; Daniel Raftery; Eric S McLamore; D Marshall Porterfield; Shawn S Donkin; Brian Bequette; Dorothy Teegarden
Journal:  Mol Carcinog       Date:  2013-09-02       Impact factor: 4.784

Review 7.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

Review 8.  Metabolic Regulation of Apoptosis in Cancer.

Authors:  K Matsuura; K Canfield; W Feng; M Kurokawa
Journal:  Int Rev Cell Mol Biol       Date:  2016-07-30       Impact factor: 6.813

9.  The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Authors:  Lu-Zhe Pan; Dae-Gyun Ahn; Tanveer Sharif; Derek Clements; Shashi A Gujar; Patrick W K Lee
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

Review 10.  Metabolic regulation of oxygen and redox homeostasis by p53: lessons from evolutionary biology?

Authors:  Jie Zhuang; Wenzhe Ma; Cory U Lago; Paul M Hwang
Journal:  Free Radic Biol Med       Date:  2012-07-25       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.